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18.6 UI/KG (14.2–19.6) for patients undergoing urgent surgery, 22.3 UI/KG (19.2–24, 
n: 41) for patients with overdose. In 66%, a risk factor of overdose was identiﬁed: 
age 75 years (63%), comorbidity (15% like diabetes). The median cost of PCC 
treatment was a888/patient (a592–a888) representing 9.3% of the total hospitalisa-
tion cost paid by national health insurance for those 91 patients. CONCLUSIONS: 
PCC was used according to the recommendations and in respect of the health care 
regulations for reimbursement. The high increase of prescription observed in 2008, 
mainly in the emergency department (48%), can be explained by a change of medical 
practices and prescribing behaviour since the new recommendations.
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OBJECTIVES: According to WHO data approximately 1.6 billion adults are over-
weight with at least 400 million being obese (BMI  30). In Western Europe up to 
4% of total expenditures on health care are spent on managing obesity and obesity 
dependent chronic diseases including diabetes, cardiovascular diseases and cancer. The 
aim of this systematic review was to ﬁnd studies on direct cost estimates of obesity 
and its comorbidities in Poland. METHODS: Search and selection of data was based 
on a protocol developed before proceeding with the search and compilation of data. 
Two researchers independently assessed publications according to pre-deﬁned inclu-
sion criteria and with regard to study methodology. The review covered following 
databases: MEDLINE, EMBASE and PBL (Polish Medical Bibliography). Last update 
of the search results have been made on May 10, 2009. RESULTS: In the result of 
the systematic review only 2 studies were found: Szponar et al. 2006 and Krzyza-
nowska et al. 2008. In those studies direct costs of treating obesity and associated 
diseases have been estimated at between 20 to 30% of the total health care expendi-
tures in Poland. Based on OECD data it gives the amount of 8.15 to 12.2 billion USD 
according to PPP in 2008. CONCLUSIONS: Economic burden of obesity and its 
comorbidities in Poland is undoubtedly signiﬁcant. In 4 European countries with 
obesity prevalence similar to Poland (Portugal, Norway, Belgium and Sweden), the 
cost of treating obesity and associated diseases has been estimated on average at 
0.32% GDP. If the cost of obesity and its comorbidities in Poland amounted also to 
0.32% of GDP, the total burden of disease could have been estimated at 1.95 billion 
USD. We conclude that speciﬁc Polish data from the two above mentioned studies can 
be signiﬁcantly overestimated and there is an urgent need for further research in order 
to estimate the true value of these costs.
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OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH and pharmacoeconomic advisory committee evaluated the applicants dossier for 
the biologic drug ustekinumb (Stelara®, Jannssen Cilag Slovakia) for the treatment of 
psoriasis. The pharmacoeconomic part of the application fulﬁled all legislative aspects. 
The CEA shows that ustekinumab is more cost effective in cost of theraphy responder 
analysis vs. other biologics in the Slovak market for psoriasis treatment by 2%—60%. 
The price sensitivity analysis of comparators was done. The reassessment of CEA after 
massive price cut of comparators (up to 32%, due to international price referencing) 
has showed the positive results for ustekinumab and robustness of previous price 
sensitivity analysis. CONCLUSIONS: The focus of the MoH drug policy is on more 
rational spendings , especially on reference pricing and HTA. There are ﬁrst results 
of these new procedures, where the real impact of the HTA in the decision processes 
is demonstrated. Ustekinumb a new agent in therapy of psoriasis fulﬁlled the necessary 
legislative conditions including pharamacoeconomic aspects to be listed in the positive 
reimbursement list.
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OBJECTIVES: To describe the prescription pattern of rimonabant in relation to the 
approved indications and the stated limitations of reimbursement. Secondly to 
compare the efﬁciency and adverse effects in rimonabant treated patients with the 
impact of conventional care in matched controls without rimonabant treatment during 
a follow up period of up to 12 months. METHODS: The survey was based on retro-
spective collection of data through a speciﬁed extraction and data management 
method, Pygargus Customized eXtraction Program (CXP) developed to extract patient 
data from an Electronic Health Record (EHR) system (Profdoc Journal III). Centers 
were selected with a wide socio-economic and geographical spread. RESULTS: Body 
mass index (BMI) was available in 922 patients out of 1477 (62%). Of those patients, 
93% were prescribed rimonabant according to the indication and 79% within the 
reimbursement criteria. In reality, 97% of the total cohort obtained reimbursement. 
Patients prescribed rimonabant for at least 6 months showed a mean weight reduction 
of 6.0 kg after 12 months compared to 0.4 kg in controls. The mean decrease in 
HbA1c was 0.3% in patients with type-2 diabetes versus 0.0% in controls. More than 
half of patients and controls (54.4 vs. 54.3 %) had a documented psychiatric illness 
such as anxiety, depressive disorders or sleep disturbances at baseline. There was no 
increase in the co-prescription of anxiolytics /sedatives /anti-depressant over time 
comparing rimonabant treated patients with controls. CONCLUSIONS: The majority 
of patients were prescribed rimonabant according to the given rules for indication and 
reimbursement. Weight reduction in the total cohort and reduction of HbA1c in 
patients with type 2 diabetes during the follow up year, were of similar magnitude as 
reported in various clinical trials. The safety analysis did not signal any increase in 
adverse events including psychiatric illness in patients treated with rimonabant more 
than six months.
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OBJECTIVES: To review recommendations of Health Technology Assessment (HTA) 
reports on sibutramine and orlistat in the treatment of obesity from France (HAS), 
UK (NICE), Sweden (TLV), Belgium (KCE) and Canada (CADTH). METHODS: HTA 
reports were identiﬁed by searching each HTA agency’s homepages using “sibu-
tramine” OR “orlistat” as keywords. Results were categorised as Recommended, 
Restricted recommended and Not Recommended in comparison to the indication for 
marketing authorisation given by EMEA. RESULTS: A total of eleven HTA reports 
were identiﬁed; six assessing orlistat and ﬁve sibutramine. Four HTA-reports on orli-
stat gave a positive recommendation while the remaining HTA reports did not recom-
mend use/funding. Reasons for not recommending orlistat included; insufﬁcient data 
to quantify obesity-related morbidity and mortality, uncertainties in compliance due 
to side effects, treatment effect was not maintained after discontinuation, lack of long 
term safety data, and poor deﬁnition of indication “metabolic syndrome”. For sibu-
tramine, three reports concluded Recommended, one Restricted recommended and 
one Not recommended. Reasons for a negative and restricted recommendation 
included; insufﬁcient data to quantify obesity-related morbidity and mortality, and 
lack of long term safety data. CONCLUSIONS: Quantity of effect of weight loss on 
morbidity and mortality, deﬁning an appropriate indication for initiating pharmaco-
logical treatment and adequate provision of data on long-term safety and effectiveness 
appears to be main issues driving a negative recommendation. These issues must be 
addressed in the development of a clinical documentation of future pharmacological 
treatments of obesity. It is interesting to notice that similar evidences lead to very           
contradictory outcome reﬂecting broader way to scrutinize evidences for HTA decision 
making.
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OBJECTIVES: To clarify how the standard estimate of incremental cost-effectiveness 
ratio (ICER) theoretically changes, affected by the uncertainty accompanied with sta-
tistical errors and probability of truth in evidence-based practice, and further to 
investigate how the ‘risk’-adjusted ICER (r-ICER) could be used in the analysis of 
efﬁciency frontier by IQWiG. METHODS: A decision analysis was performed using: 
1) probability of truth, 1 – p, for a null hypothesis (or p for the alternative hypothesis), 
2) type I error (A), and 3) type II error (B).The decision tree modeled a patient facing 
the alternative decisions for treatment: evidence-based (Teb) or conventional (Tc), 
considering the choices: 1) Tc: if no evidence available about a new treatment A, then 
the patient takes a conventional treatment B, and 2) Teb: if positive evidence of a 
clinical trial available, then take the treatment A, whereas if the evidence is negative, 
take the treatment B. Given a pair of beneﬁt and cost for the treatments A and B, 
respectively noted as (Ea, Ca) and (Eb, Cb) at the terminal node, then the operations 
